MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Tilade (nedocromil sodium)

Company: Rhone Poulenc Rorer
Approval Status: Approved November 1997
Treatment for: asthma
Areas: Respiratory
Possible similar drugs: Tilade; Tilade

| General Information | Clinical Results | Side Effects |


General Information

Tilade Nebulizer Solution (nedocromil sodium inhalation solution) has been approved as a treatment for mild to moderate asthma in patients two years of age and older. Tilade Solution is a new dosage form of Rhone-Poulenc Rorer's Tilade Inhaler, an inhaled nonsteroidal anti-inflammatory agent for the preventive management of mild to moderate asthma. A nebulizer is a device used to reduce liquid medication to fine particles so that it can be delivered by inhalation to the respiratory tract.


Clinical Results

The safety and efficacy of Tilade Nebulizer Solution was studied in eight randomized, double-blind, parallel, placebo-controlled U.S. clinical trials of 1,403 patients with mild to moderate asthma. Patients treated with Tilade Nebulizer Solution experienced statistically significant reductions in asthma symptoms, and a greater increase in morning peak expiratory flow rates vs. placebo.


Side Effects

The most common adverse events from all eight clinical trials reported frequently for those receiving Tilade Nebulizer Solution vs. placebo were sore throat, sinusitis, and fever.




< back to top

Tilade Drug Information

The Tilade drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.